Professors Simon Rule, Peter Hillmen and John Gribben are leading UK clinical researchers with a special interest in CLL. In this brief news report from this year's EHA meeting in Milan they share insights into the promising future for CLL treatment as greater understanding of the biology of this complex disease brings with it an increasing range of potential therapies.
Who we are
We are a patient led UK charity, our mission is to support and empower CLL patients, their families and their carers.
Read moreOur 24 hour membership telephone number is: 0800 977 4396
About CLL
CLL is a malignancy of B lymphocytes, one of several types of cells of the immune system.
Read moreAbout CLL
Donate
Donate to support our CLL community
Donate nowHealthUnlocked
Connect to others who understand
Open in a new tabThis page was last reviewed 22nd October 2019. Next review October 2022
Send us feedback about this pageSend us feedback about this page
Help us to ensure we deliver the best content we can by giving us feedback about this page, good or bad. Please provide an email address if you would like us to respond to your feedback.
"*" indicates required fields
